Thermo Fisher Scientific Inc. $TMO Shares Acquired by Vise Technologies Inc.

Vise Technologies Inc. increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 48.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,494 shares of the medical research company’s stock after acquiring an additional 4,382 shares during the period. Vise Technologies Inc.’s holdings in Thermo Fisher Scientific were worth $9,109,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. BlackRock Inc. acquired a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $15,501,867,000. Corient Private Wealth LP purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $382,547,000. Bank of New York Mellon Corp acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth about $1,974,561,000. Bank of America Corp DE acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth about $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Thermo Fisher Scientific by 0.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after buying an additional 22,827 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent research reports. Argus lifted their price target on shares of Thermo Fisher Scientific from $560.00 to $780.00 and gave the stock a “buy” rating in a research note on Friday. HSBC upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 1st. Scotiabank started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an “outperform” rating on the stock. Royal Bank Of Canada lifted their price objective on shares of Thermo Fisher Scientific from $580.00 to $730.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 22nd. Finally, Guggenheim assumed coverage on shares of Thermo Fisher Scientific in a research note on Thursday, October 15th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $689.10.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $696.78 on Monday. The stock has a 50 day moving average price of $654.87 and a 200 day moving average price of $552.94. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $257.63 billion, a price-to-earnings ratio of 36.75, a price-to-earnings-growth ratio of 2.84 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $711.85.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. The company had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the company earned $5.79 earnings per share. Research analysts predict that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Lisa Britt sold 11,440 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 76,199 shares of company stock valued at $45,896,780. Corporate insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.